Characteristic | Value$ |
---|---|
Age, years | 40.0 ± 12.4 |
Sex, no. (%) | |
 Male | 50 (53.8) |
 Female | 43 (46.2) |
BM blasts, % | 0.4 ± 0.3 |
HB, g/dL | 91.0 ± 25.3 |
WBC, × 109/L | 9.2 ± 15.9 |
PLT, × 109/L | 69.5 ± 66.4 |
ECOG PS, no. (%) | |
 0 | 34 (36.6) |
 1 | 42 (45.2) |
 2 | 16 (17.2) |
 3 | 1 (1.1) |
FAB classification, no. (%) | |
 M0 | 2 (2.2) |
 M1 | 3 (3.2) |
 M2 | 49 (52.7) |
 M4 | 14 (15.1) |
 M5 | 24 (25.8) |
 M6 | 1 (1.1) |
Diagnosis, no. (%) | |
 Refractory | 37 (39.8) |
 Early relapse | 38 (40.9) |
 Late relapse | 18 (19.4) |
Antecedent hematologic disorders, no. (%) | |
 Myelodysplastic syndromes | 3 (3.2) |
 Aplastic anemia | 1 (1.1) |
Prior therapies, no. (%) | |
 0–5 | 52 (55.9) |
 6–10 | 28 (30.1) |
 ≥ 11 | 13 (14.0) |
Prior therapy, no. (%) | |
 Prior epigenetic agents | 17 (18.3) |
 Prior allogeneic stem cell transplant | 2 (2.2) |
Karyotype, no. (%) | |
 Normal karyotype | 54 (58.1) |
 Complex karyotype# | 9 (9.7) |
 T (8; 21) | 13 (14.0) |
Mutation counts, no. (%)* | |
 0 | 12 (13.6) |
 1 | 20 (22.7) |
 2 | 22 (25.0) |
 3 | 19 (21.6) |
 4 | 12 (13.6) |
 5 | 3 (3.4) |